Mitsubishi Chemical Holdings (4188) AI Stock Analysis

• Market Cap: ¥1.35T
• Dividend Yield: 3.5%
• Average Volume (3M): 5.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -11.50%
• EPS Growth: 25.86%
• Country: JP
• Employees: 66,358
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): N/A
• Shares Outstanding: 1,441,467,200
• 10 Day Avg. Volume: 5,007,700
• 30 Day Avg. Volume: 5,460,770
• PEG Ratio: -0.37
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.24
• P/FCF Ratio: 4.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,100.00
• Price Target Upside: 15.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ¥1,143.00 ▲(19.89% Upside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven by strong technical momentum and a reasonable valuation with a ~3.0% dividend yield. These positives are tempered by only mid-tier financial performance, with declining TTM revenue, thin net margins, and a still-meaningful debt load despite improving leverage and solid cash flow.

Positive Factors

Diversified, higher-value portfolio

Mitsubishi Chemical's exposure to chemicals, specialty materials, pharmaceuticals and healthcare creates portfolio diversification across cycles. Specialty/pharma offerings involve customer qualification and differentiated formulations, which support stickier demand and pricing power, improving long-term revenue resilience.

Solid cash generation

Consistent positive FCF growth provides durable internal funding for capex, R&D, dividends, and debt reduction. Over a 2–6 month horizon, steady cash generation enhances financial flexibility and reduces reliance on external financing during industry cyclicality.

Improving leverage and capital base

Leverage reduction and equity growth strengthen the balance sheet, lowering refinancing and solvency risk. Improved capital structure increases capacity to fund strategic investments or withstand downturns, making the company structurally more resilient over the medium term.

Negative Factors

Declining revenue trend

A shrinking top line signals demand or mix weakness that can persist across cycles absent new growth drivers. Over months, continued revenue contraction pressures scale economics, reduces leverage for investments, and makes margin recovery dependent on product mix or pricing improvements.

Thin profitability

Low net margins indicate limited ability to absorb raw-material, energy, or FX shocks and constrain retained earnings. Structurally thin profitability reduces room for reinvestment and slows balance sheet repair, making the firm more sensitive to cyclical downturns and cost inflation.

Weak cash conversion vs earnings

Despite positive FCF growth, low conversion of reported earnings into free cash implies working-capital swings or heavy capex. Structurally weak conversion limits true liquidity available for debt reduction or strategic moves, keeping vulnerability to funding stress in tougher periods.

Mitsubishi Chemical Holdings Business Overview & Revenue Model

Company Description

Mitsubishi Chemical Group Corporation provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally. The company's performance products include specialty chemicals, functional food materials, inorganic materials, electronic and electrical components and products, molding and processed products, film and sheet products, synthetic paper and fiber, carbon fiber, equipment, instruments and systems, materials and products for industrial use, construction materials, civil engineering materials, aqua-related materials and products, leisure, sports, and daily goods. Its health care products comprise pharmaceuticals, pharmaceutical formulation materials and related products, drug discovery solutions, diagnostic reagents and instruments, health apparatus and instruments for medical use, medical support, nursing care and health support, and clinical examination and service. The company also offers industrial materials, such as basic chemicals, carbon materials, synthetic resins, and industrial gases; and engineering, information systems, analysis and inspection, packaging and logistics, survey, consulting, and other services. In addition, it provides engineering, transportation, and warehousing services. The company was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Mitsubishi Chemical Holdings generates revenue primarily through the production and sale of chemical products across multiple sectors. Key revenue streams include the sales of performance materials, such as engineering plastics and films, which are utilized in automotive, electronics, and packaging industries. Additionally, the company earns income from its healthcare segment, which provides medical and pharmaceutical products. Strategic partnerships with other companies and research institutions also contribute to revenue through collaborative projects and joint ventures, enhancing product development and market reach. The company's focus on innovation and sustainability helps to maintain its competitive edge and drive sales growth.

Mitsubishi Chemical Holdings Financial Statement Overview

Summary

Fundamentals are mixed: TTM revenue declined (-3.8%) and net margin is thin (~2.4%), indicating margin pressure. Offsetting this, cash generation is relatively solid with positive free-cash-flow growth (~7.9%) and leverage has improved versus prior years, though debt remains meaningful (debt-to-equity ~1.03).

Income Statement

Revenue is modestly down in TTM (Trailing-Twelve-Months) (-3.8%), following a largely flat to mixed top-line trend in recent annual periods. Profitability is positive but thin for the industry in TTM, with low net margin (~2.4%) despite a relatively steady gross margin (~29%). Operating profitability has also compressed versus prior stronger years (e.g., higher operating and EBITDA margins in 2022–2024), indicating a less favorable pricing/mix or cost environment. A key positive is the return to solid profitability versus the 2021 loss, but earnings remain volatile across cycles.

Balance Sheet

Leverage is meaningful, with debt roughly in line with equity in TTM (debt-to-equity ~1.03), though improved from higher leverage in earlier years (peaking near ~1.90 in 2021). Equity has grown over time, supporting a stronger capital base, and returns on equity in TTM are moderate (~6.5%), better than the latest annual figure but below peak levels seen in stronger years. Overall, the balance sheet looks serviceable with improving leverage trends, but still carries above-average debt load that can pressure resilience in down cycles.

Cash Flow

Cash generation is a relative strength: operating cash flow and free cash flow are solid in TTM, with free cash flow growth positive (~7.9%). However, cash conversion is not especially strong—free cash flow is well below reported net income (free cash flow to net income ~0.39 in TTM), suggesting working-capital swings and/or higher capital spending are absorbing cash. Coverage metrics are steady but not high, implying cash flow provides a reasonable cushion, though not an exceptional one for the current debt profile.

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	3.81T	4.41T	4.39T	4.63T	3.98T	3.26T
Gross Profit	1.11T	1.28T	1.15T	1.24T	1.11T	926.25B
EBITDA	396.84B	481.62B	561.06B	456.72B	542.84B	283.92B
Net Income	91.08B	45.02B	119.60B	96.46B	177.16B	-7.56B
Balance Sheet
Total Assets	5.82T	5.89T	6.10T	5.77T	5.57T	5.29T
Cash, Cash Equivalents and Short-Term Investments	366.46B	392.25B	377.73B	297.22B	245.79B	349.58B
Total Debt	1.90T	2.04T	2.20T	2.24T	2.16T	2.35T
Total Liabilities	3.34T	3.61T	3.83T	3.79T	3.73T	3.72T
Stockholders Equity	1.85T	1.74T	1.76T	1.56T	1.46T	1.24T
Cash Flow
Free Cash Flow	176.77B	238.31B	190.67B	74.19B	89.21B	210.12B
Operating Cash Flow	457.69B	552.85B	465.15B	355.19B	346.87B	467.13B
Investing Cash Flow	58.73B	-275.43B	-246.09B	-247.63B	-128.78B	-217.01B
Financing Cash Flow	-440.43B	-246.65B	-241.72B	-60.78B	-336.28B	-142.77B

Mitsubishi Chemical Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 953.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4188, the sentiment is Positive. The current price of 953.4 is below the 20-day moving average (MA) of 1118.52, below the 50-day MA of 1030.32, and above the 200-day MA of 864.76, indicating a neutral trend. The MACD of 32.16 indicates Positive momentum. The RSI at 54.27 is Neutral, neither overbought nor oversold. The STOCH value of 63.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4188.

Mitsubishi Chemical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4063	75 Outperform	¥12.07T	18.04	10.87%	2.17%	3.77%	0.35%
3407	68 Neutral	¥2.31T	8.67	7.48%	2.89%	3.55%	95.65%
4188	66 Neutral	¥1.35T	-66.09	1.09%	3.50%	-11.50%	25.86%
4042	66 Neutral	¥835.30B	10.74	4.79%	4.21%	-1.21%	-27.21%
4005	62 Neutral	¥836.90B	3.83	8.79%	2.68%	-1.64%	―
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
4004	58 Neutral	¥2.27T	40.66	1.67%	1.00%	-1.90%	-71.97%

Mitsubishi Chemical Holdings Corporate Events

Mitsubishi Chemical Group Outlines Q3 FY2025 Operational Performance and Outlook

Mitsubishi Chemical Group Corporation has released an operational summary for the third quarter of the fiscal year ending March 31, 2026, outlining its consolidated financial performance, cash flows, and balance sheet position. The report details sales revenue and core operating income by business segment, analyzes profitability trends and special items, and provides an updated forecast for FY2025, including expectations by segment and across key core markets. While specific figures are not disclosed in the outline, the breadth of segment analysis and forward projections underscores the group’s focus on monitoring earnings quality, margin performance, and market conditions, offering investors and other stakeholders structured visibility into how its diverse businesses are performing and expected to evolve through the fiscal year.

The most recent analyst rating on (JP:4188) stock is a Buy with a Yen1151.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.

Mitsubishi Chemical Slashes Profit Outlook on One-Off Restructuring Charges

Mitsubishi Chemical Group has sharply cut its profit outlook for the fiscal year ending March 31, 2026, while keeping sales and core operating income forecasts unchanged at ¥3.672 trillion and ¥250 billion, respectively. The company now expects operating income of ¥70 billion and net income attributable to owners of the parent of ¥47 billion, reductions of about 60% and 62% from its previous forecast, reflecting additional non-recurring losses tied to structural reform measures, including withdrawal from its coke and carbon materials business. Segment-level core earnings projections remain intact, underlining that the downgrade is driven by one-off charges rather than a deterioration in underlying operations, as the group continues its portfolio restructuring following the separation of Mitsubishi Tanabe Pharma.

The most recent analyst rating on (JP:4188) stock is a Buy with a Yen1151.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.

Mitsubishi Chemical Group Profits Rise Despite Lower Revenue After Portfolio Restructuring

For the nine months to 31 December 2025, Mitsubishi Chemical Group reported an 8.2% year-on-year decline in sales revenue to ¥2.74 trillion from continuing operations, while core operating income slipped 2.4% to ¥185.6 billion and operating income fell 22.2%. Despite lower revenue and operating profit, net income attributable to owners of the parent surged 77.6% to ¥105.4 billion and basic earnings per share rose to ¥76.70, supported partly by portfolio changes and the classification of its former pharmaceuticals business as discontinued operations; equity attributable to owners also increased, lifting the equity ratio to 31.8%. The company kept its full-year dividend forecast unchanged at ¥32 per share and revised its fiscal 2025 earnings outlook, projecting a 7.0% drop in annual sales revenue but higher core operating income, alongside a sharp fall in operating income and income before taxes, underscoring ongoing restructuring effects and margin pressures even as profitability to shareholders improves.

The most recent analyst rating on (JP:4188) stock is a Buy with a Yen1151.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.

Mitsubishi Chemical to Exit Coke and Carbon Materials Business, Booking ¥85 Billion Loss

Mitsubishi Chemical Group Corporation will withdraw from its coke and carbon materials (needle coke, pitch coke) business, a segment within the coal operations of subsidiary Mitsubishi Chemical Corporation, following a prolonged slump in the overseas coke market driven by weak steel demand and oversupply from China and new Indonesian capacity. The decision, which affects operations at the Kagawa Plant but excludes pitch-based carbon fibers and anode materials, reflects a strategic portfolio shift away from structurally unprofitable coal-related activities, with production scheduled to end in the second half of fiscal 2027 and around 600 employees to be covered by support measures. The group expects to book approximately ¥85 billion in total non-recurring losses tied to impairment, equipment removal and employee support costs, with ¥19 billion recognized as extraordinary losses in the third quarter and roughly ¥66 billion estimated for the fourth quarter of the fiscal year ending March 2026, and will revise its full-year earnings forecast once the financial impact is fully assessed.

The most recent analyst rating on (JP:4188) stock is a Buy with a Yen1132.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.

Mitsubishi Chemical Group to Consolidate CVC Operations Under Mitsubishi Chemical Corporation

Mitsubishi Chemical Group Corporation will transfer its corporate venture capital (CVC) business and related assets to its consolidated subsidiary Mitsubishi Chemical Corporation via a simplified absorption-type company split effective April 1, 2026. The move will shift ownership of Diamond Edge Ventures, stakes in several industrial innovation venture funds, and shareholdings in multiple startups into Mitsubishi Chemical Corporation’s Innovation Division, aligning the venture arm with the technology development function that was reorganized under the subsidiary in April 2025; the restructuring involves no shareholder meetings, stock allocation or capital change, and is intended to streamline governance and accelerate innovation initiatives by consolidating business operations and associated investment assets under a single operating entity.

The most recent analyst rating on (JP:4188) stock is a Hold with a Yen1100.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.

Mitsubishi Chemical’s Workforce Restructuring Program Results in Significant Cost Savings

Mitsubishi Chemical Corporation announced the results of its Next-stage Support Program, aimed at restructuring its workforce by offering retirement and reemployment support to eligible employees. The program resulted in 1,273 applicants, leading to an anticipated annual reduction in labor expenses by approximately 16 billion yen. Despite an extraordinary loss of 27.7 billion yen due to restructuring costs, the company expects these changes to contribute positively to its financial performance in the long term.

The most recent analyst rating on (JP:4188) stock is a Hold with a Yen860.00 price target. To see the full list of analyst forecasts on Mitsubishi Chemical Holdings stock, see the JP:4188 Stock Forecast page.